Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer
A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
- A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
- In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
- How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
- Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?